Cancer treatment is an area of continuous improvement. Therapy is becoming more targeted
and the use of anti-angiogenic agents in multiple cancers, specifically tyrosine kinase …

Abstract Purpose of Review The purpose of this paper is to identify commonly used tyrosine
kinase inhibitors (TKIs) that are associated with hypertension, primarily, vascular endothelial …

Tyrosine kinase receptor inhibitors (TKIs) are a relatively new class of targeted anti-cancer
agents with vascular endothelial growth factor signalling pathway–inhibiting properties …

Contemporary anticancer drugs have significantly improved cancer survival at the expense
of cardiovascular toxicities, including heart disease, thromboembolic disease, and …

The Oncology Grand Rounds series is designed to place original reports published in the
Journal into clinical context. A case presentation is followed by a description of diagnostic …

Hypertension is a common comorbidity in patients receiving antiangiogenic therapy. Prior
studies have reported worsening or new‑onset hypertension as an adverse event of …

Background Rapid progress over the last decade has added numerous agents targeting
specific cellular signaling pathways to the treatment armamentarium for advanced cancer …

Hypertension is one of the most common comorbidities in cancer patients with malignancy,
in particular, in the elderly. On the other hand, hypertension is a long-term consequence of …

Cancer is considered one of the leading causes of mortality worldwide. At the same time,
hypertension is recognized as one of the most common comorbidities in cancer patients …

Background Tyrosine kinase inhibitors (TKIs) have been developed during the last decade
that target the vascular endothelial growth factor receptor (VEGFR) are currently being …